Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹104.80
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.66B
Enterprise Value₹2.06K
Total Cash (Recent Filing)₹13.85M
Total Debt (Recent Filing)₹488.69M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding36,152,710
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionSubstantial debt reduction improves financial flexibility and lowers balance-sheet risk. If maintained, the lower borrowing burden should reduce refinancing pressure and leave more capacity to support pharmaceutical operations and future investment.
Positive Operating Cash FlowPositive operating cash flow indicates that the core business still converts activity into cash even during a loss-making period. This provides some internal funding support and is a useful base for restoring profitability if operating performance improves.
Positive Equity BaseA positive equity base provides a more stable capital foundation than the company had during its earlier negative-equity period. Combined with lower debt, it reduces immediate solvency pressure and supports continued participation in pharmaceutical manufacturing.
Bears Say
Revenue Contraction And Profit ReversalThe latest deterioration shows that demand, pricing, or cost absorption remains inconsistent. A revenue decline accompanied by a sharp swing into losses weakens confidence in earnings durability and may limit internally funded growth over the next several quarters.
Persistent Negative Free Cash FlowSustained negative free cash flow means operating cash has not covered investment and other capital needs. This limits self-funding capacity and could require additional borrowing or external capital, offsetting some benefits from recent debt reduction.
Unstable Historical Financial ProfileRecent balance-sheet repair has not removed the risk created by the company’s volatile history. Prior negative equity, high leverage, and repeated losses indicate limited resilience if pharmaceutical margins weaken or cash needs rise again.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹104.80 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.66B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Nov 14, 2026 which is in 81 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on Aug 10, 2026. The company reported ₹0.571 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 36,152,710 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of ₹0.571 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.996%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―